RELAY THERAPEUTICS INC. - COMMON STOCK

Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025

28 Apr 2025 16:05:39 By Nasdaq GlobeNewswire

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

26 Feb 2025 16:05:00 By Nasdaq GlobeNewswire

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

24 Feb 2025 16:05:56 By Nasdaq GlobeNewswire

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025

19 Feb 2025 16:05:31 By Nasdaq GlobeNewswire

Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

07 Jan 2025 16:05:00 By Nasdaq GlobeNewswire

Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

11 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium

09 Dec 2024 16:05:30 By Nasdaq GlobeNewswire

Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

03 Dec 2024 08:00:15 By Nasdaq GlobeNewswire

Relay Therapeutics to Participate in Upcoming Investor Conferences

07 Nov 2024 16:05:11 By Nasdaq GlobeNewswire

Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights

06 Nov 2024 16:05:29 By Nasdaq GlobeNewswire

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024

30 Oct 2024 16:05:26 By Nasdaq GlobeNewswire

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

10 Sep 2024 20:21:51 By Nasdaq GlobeNewswire

Relay Therapeutics Announces Proposed Public Offering of Common Stock

09 Sep 2024 16:34:20 By Nasdaq GlobeNewswire

Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival

09 Sep 2024 06:55:20 By Nasdaq GlobeNewswire

Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024

06 Sep 2024 16:05:36 By Nasdaq GlobeNewswire

Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights

06 Aug 2024 16:05:26 By Nasdaq GlobeNewswire

Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024

30 Jul 2024 16:05:38 By Nasdaq GlobeNewswire

Relay Therapeutics Discloses Three New Programs at New Program & Platform Event

06 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608

05 Jun 2024 16:05:03 By Nasdaq GlobeNewswire

Relay Therapeutics to Participate in Upcoming Investor Conferences

21 May 2024 16:05:35 By Nasdaq GlobeNewswire